<DOC>
	<DOCNO>NCT01114308</DOCNO>
	<brief_summary>Probuphine ( buprenorphine implant ) implant place skin contain buprenorphine ( BPN ) . BPN approve treatment opioid dependence . This study confirm efficacy Probuphine vs. placebo compare Probuphine treatment verse treatment sublingual buprenorphine treatment patient opioid dependence .</brief_summary>
	<brief_title>A Six-Month Randomized Controlled Trial ( RCT ) Probuphine Safety Efficacy Opioid Addiction</brief_title>
	<detailed_description />
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Voluntarily provide write informed consent prior conduct studyrelated procedure Male female , 1865 year age Meet DSMIVTR criterion current opioid dependence Females childbearing potential fertile male , must use reliable mean contraception Current diagnosis Acquired Immune Deficiency Syndrome ( AIDS ) Received medicationassisted treatment opioid dependence ( e.g. , methadone , BPN ) within previous 90 day Current diagnosis chronic pain require opioids treatment Candidates shortterm opioid treatment ( &lt; 6 month ) , opioid detoxification therapy Pregnant lactate female ? Previous hypersensitivity allergy BPN , EVAcontaining substance , naloxone Current use agent metabolize Cytochrome P450 3A4 ( CYP 3A4 ) azole antifungal ( e.g. , ketoconazole ) , macrolide antibiotic ( e.g. , erythromycin ) , protease inhibitor ( e.g. , ritonavir , indinavir , saquinavir ) History coagulopathy within past 90 day , and/or current anticoagulant therapy warfarin Meet DSMIVTR criterion dependence psychoactive substance opioids nicotine ( e.g. , alcohol , sedative ) Significant medical psychiatric symptom , cognitive impairment , factor opinion Investigator would preclude compliance protocol , subject safety , adequate cooperation study , obtain inform consent Current medical condition severe respiratory insufficiency may prevent subject safely participate study , pending legal action could prohibit participation compliance study Exposure investigational drug within previous 8 week Previous exposure Probuphine , prior implantation placebo implant context Probuphine clinical trial Presence aspartate aminotransferase ( AST ) level great equal 3 X upper limit normal , alanine aminotransferase ( ALT ) level great equal 3 X upper limit normal , total bilirubin great equal 1.5 X upper limit normal , creatinine great 1.5 X upper limit normal screen laboratory assessment Clinically significant low platelet count screen laboratory assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>opioid dependence</keyword>
	<keyword>opioid addiction</keyword>
	<keyword>buprenorphine</keyword>
	<keyword>implant</keyword>
	<keyword>methadone</keyword>
	<keyword>heroin</keyword>
	<keyword>suboxone</keyword>
	<keyword>opioid pain medication</keyword>
	<keyword>opioid withdrawal</keyword>
</DOC>